We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-3.07%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
-$197M
Cap. Flow
-$69.4M
Cap. Flow %
-6.26%
Top 10 Hldgs %
86.66%
Holding
22
New
3
Increased
2
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$18.9M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$16.2M
3
SLDB icon
Solid Biosciences
SLDB
+$12.2M
4
IRON icon
Disc Medicine
IRON
+$9.8M
5
XLO icon
Xilio Therapeutics
XLO
+$1.13M

Top Sells

Rank Stock Value
1
HTFL
Heartflow Inc
HTFL
+$54.3M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$23M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$22.1M
4
MRSN
Mersana Therapeutics
MRSN
+$10M
5
UPB
Upstream Bio Inc
UPB
+$8.32M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HTFL
1
Heartflow Inc
HTFL
$2.47B
$254M 22.93%
10,448,158
-2,000,000
-16% -$54.3M
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.37B
$234M 21.09%
7,306,566
– –
OLMA icon
3
Olema Pharmaceuticals
OLMA
$1.05B
$111M 10.05%
7,473,238
-1,035,403
-12% -$23M
SVRA icon
4
Savara
SVRA
$1.2B
$96.1M 8.67%
17,600,621
– –
PHVS icon
5
Pharvaris
PHVS
$2.43B
$75.6M 6.82%
2,675,509
-126,572
-5% -$3.38M
SLDB icon
6
Solid Biosciences
SLDB
$843M
$70.6M 6.37%
9,808,819
+1,897,150
+24% +$12.2M
XFOR icon
7
X4 Pharmaceuticals
XFOR
$440M
$32.9M 2.97%
7,967,454
– –
DNTH icon
8
Dianthus Therapeutics
DNTH
$6.05B
$30.4M 2.74%
362,470
-381,122
-51% -$22.1M
ANNX icon
9
Annexon
ANNX
$895M
$28.9M 2.6%
5,212,674
-36,395
-0.7% -$205K
KYTX icon
10
Kyverna Therapeutics
KYTX
$479M
$26.8M 2.42%
3,110,000
– –
CABA icon
11
Cabaletta Bio
CABA
$458M
$26M 2.35%
9,677,125
– –
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
$25.2M 2.27%
+635,000
New +$16.2M
ALKS icon
13
Alkermes
ALKS
$8.23B
$21.6M 1.95%
+610,000
New +$18.9M
RPID icon
14
Rapid Micro Biosystems
RPID
$85.7M
$19.1M 1.73%
8,434,560
– –
CCCC icon
15
C4 Therapeutics
CCCC
$408M
$18.9M 1.7%
7,171,910
– –
AVIR icon
16
Atea Pharmaceuticals
AVIR
$407M
$12.7M 1.15%
2,360,638
-125,000
-5% -$574K
IRON icon
17
Disc Medicine
IRON
$2.98B
$9.03M 0.81%
+141,234
New +$9.8M
UPB
18
Upstream Bio Inc
UPB
$384M
$7.8M 0.7%
867,211
-462,333
-35% -$8.32M
XLO icon
19
Xilio Therapeutics
XLO
$60.2M
$5.58M 0.5%
664,021
+137,401
+26% +$1.13M
NAMSW icon
20
NewAmsterdam Pharma Warrant
NAMSW
$78.2M
$2M 0.18%
99,999
– –
MRSN
21
DELISTED
Mersana Therapeutics
MRSN
– –
-346,545
Closed -$10M
TNGX icon
22
Tango Therapeutics
TNGX
$4.48B
– –
-653,493
Closed -$5.79M

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q1 2026 Portfolio in Review

As of Q1 2026, Bain Capital Life Sciences Investors held 22 positions worth $1.11B, down 15% from $1.31B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $69.4M in Q1 2026, closing 2 positions and reducing 7 holdings. Its most notable exit was Mersana Therapeutics, an estimated $10M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors opened a new position in Alkermes worth $21.6M.

  • Bain Capital Life Sciences Investors's largest Q1 2026 buy was Alkermes: 610,000 shares worth $21.6M.
  • Bain Capital Life Sciences Investors added most to Solid Biosciences in Q1 2026, an estimated $12.2M increase.
  • Bain Capital Life Sciences Investors's biggest Q1 2026 reduction was Heartflow Inc, cutting an estimated $54.3M.
  • Bain Capital Life Sciences Investors fully exited Mersana Therapeutics in Q1 2026, selling an estimated $10M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 87% of its $1.11B portfolio in Q1 2026.
  • Bain Capital Life Sciences Investors opened 3 new positions and closed 2 in Q1 2026.
  • Bain Capital Life Sciences Investors's portfolio value fell 15% quarter-over-quarter to $1.11B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.